Carbapenemase-producing *Enterobacteriaceae* can efficiently hydrolyze carbapenems and most β-lactam drugs. Since the identification of New Delhi metallo-β-lactamase-1 (NDM-1) in 2008 ([@R1]), there has been great concern regarding the spread of the Ambler class B metallo-β-lactamases (MBLs). Confirmed infections with MBL-positive bacteria are rarely identified in the Philippines, but *bla*~IMP~-harboring *Enterobacteriaceae* were reported in 2014 ([@R2]), an *Escherichia coli* (sequence type \[ST\] 131) isolate harboring *bla*~NDM-1~ was reported in 2014 ([@R3]), and 2 *Klebsiella pneumoniae* (ST626 and ST903) isolates harboring *bla*~NDM-1~ and *bla*~NDM-7~ genes were reported in 2016 ([@R4]).

We performed isolate identification and antimicrobial drug susceptibility testing by using the MicroScan WalkAway 40 plus System (Beckman Coulter, Brea, CA, USA) on 1,516 gram-positive and gram-negative isolates from patients admitted to various wards in the V. Luna Medical Center, a tertiary-care military hospital in Manila, the Philippines, during August 2013--April 2016. To better assess the distribution of carbapenem resistance and the underlying molecular mechanisms of resistance, we selected gram-negative isolates with imipenem or meropenem (or both) MICs of [\>]{.ul}8 μg/mL. We used microbroth dilution susceptibility testing ([@R5]) to select and verify 130 gram-negative nonrepeat isolates (i.e., each isolate was tested once) and then tested the isolates for carbapenemase production by using the Carba NP test as previously described ([@R6]). We tested all isolates with a Carba NP--positive result for *bla*~NDM~ and *bla*~KPC~ by using a multiplex real-time PCR assay as previously described ([@R7],[@R8]); isolates with PCR-negative results were further tested, using the Xpert Carba-R PCR test with the GeneXpert IV System (both from Cepheid, Sunnyvale, CA, USA), for the presence of *bla*~NDM~, *bla*~KPC~, *bla*~VIM~, *bla*~IMP-1~, and *bla*~OXA-48~.

Of the 130 bacterial isolates tested, 45 (35%) had positive Carba NP test results and 43 (33%) harbored *bla*~NDM~; 25 (58%) of the *bla*~NDM~-carrying isolates were identified as *K. pneumoniae* ([Technical Appendix](#SD1){ref-type="local-data"}Table). None of the isolates was positive for *bla*~KPC~. Two *Pseudomonas aeruginosa* isolates that had positive Carba NP test results were negative for *bla*~NDM~ and *bla*~KPC~ but positive for *bla*~VIM~. During the collection period, we also tested 8 environmental samples collected from the hospital's neonatal intensive care unit and obstetrics and gynecology wards; 3 (38%) of the 8 isolates were positive for *bla*~NDM~ and identified as *K. pneumoniae* ([Technical Appendix](#SD1){ref-type="local-data"}Table).

We report the identification of *bla*~NDM~-positive bacterial isolates in several genera of *Enterobacteriaceae* and nonfermentative bacteria in the Philippines. This finding is particularly significant because NDM-like enzymes have a broad range of activity against most β-lactam antimicrobial drugs and are often associated with serious clinical infections ([@R9]). A higher risk for plasmid-mediated transfer of NDM-1 exists through conjugation between different gram-negative bacterial strains ([@R10]), and NDM-1 can spread rapidly via nosocomial transmission or community-acquired infection. Furthermore, although limited in number, the environmental samples in this study were also positive for *bla*~NDM~, which suggests the possibility of nosocomial transmission and local circulation.

We conducted multiplex real-time PCR testing only for *bla*~NDM~, *bla*~KPC~, *bla*~VIM~, *bla*~IMP-1~, and *bla*~OXA-48~ and did not investigate clonality; thus, further investigation into other carbapenemase genes should be conducted. In addition, further experiments should be performed to characterize the plasmids carrying the carbapenemase genes. Strengthening of multidrug-resistant microbial pathogen surveillance and antimicrobial drug stewardship is urgently needed to better characterize drug-resistance patterns and improve early detection and containment strategies in developing countries.

###### Technical Appendix

Molecular resistance mechanisms of carbapenem-resistant clinical and environmental isolates from a tertiary-care military hospital, Manila, Philippines, August 2013--April 2016.
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